Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Bupropion Hydrochloride Clear all

Conditions: Tobacco Use Disorder
Interventions: bupropion and transdermal patch, transdermal patch and nicotine inhaler; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Depression, Suicidal Ideation
Interventions: Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Dependence
Interventions: bupropion + nicotine gum, Active bupropion-Placebo gum, Placebo bupropion-Placebo gum; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
Interventions: Bupropion; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Lu AG06466, Midazolam, Metoprolol, Bupropion; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Smoking, Tobacco Use Disorder
Interventions: Bupropion SR & Varenicline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking Cessation
Interventions: All Nations Breath of Life (ANBL), Nontailored program (NT), Pharmacotherapy; Behavioral · Drug
Lead sponsor: Won Choi, PhD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Kansas City, Kansas • Oklahoma City, Oklahoma

Conditions: 1. Major Depressive Disorder
Interventions: Supplemental TMS, Standard Medication Monotherapy; Device · Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Smokers
Interventions: bupropion + nicotine patch + nicotine gum or lozenges, Placebo pill + placebo patch; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Sertraline, Bupropion; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Methamphetamine Dependence
Interventions: placebo, Naltrexone and Bupropion SR; Other · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Use Disorder, Homelessness
Interventions: Nicotine Patches, mobile contingency management (mCM), Smoking cessation counseling, Nicotine rescue method, Bupropion; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Depression
Interventions: Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Smoking
Interventions: Cognitive Behavioral Counseling, Mobile Contingency Management, Bupropion, Transdermal nicotine patch, Nicotine polacrilex, Nicotine lozenge; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions: Smoking-cessation treatment; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more

Conditions: Mental Illness
Interventions: TRIIUMPH Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head And Neck Cancer
Interventions: Placebo, Armodafinil, Minocycline, Bupropion; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Coronary Syndrome, Depressive Symptoms
Interventions: Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care, Depressive symptom screener, No intervention; Other · Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more

Conditions: Obesity
Interventions: Naltrexone-Bupropion Combination; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Non-Nicotine Agents for Smoking Cessation

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Bupropion Alone or Combined With Nicotine Gum

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

Chantix & Bupropion for Smoking Cessation

Smoking Cessation for American Indians

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

Smoking Relapse Prevention in Schizophrenia

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers

VA Augmentation and Switching Treatments for Improving Depression Outcomes

Predictors of Antidepressant Response

Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)

Smoking-Cessation and Stimulant Treatment (S-CAST)

Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH

Symptom Burden in Head and Neck Cancer

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

A Phase 1, First-in-human Study of VX-433